Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2017

Balance Sheet Related Disclosures [Abstract]

Schedule of property and equipment, net

Property and equipment, net consist of the following (in thousands):

	March 31,			December 31,
	2017			2016
Leasehold improvements	$	96		$	86
Laboratory equipment and toolings		2,441			2,264
Computer equipment		299			287
Software		692			669
Office equipment		131			129
Furniture and fixtures		747			743
		4,406			4,178
Less accumulated depreciation		(1,335	)		(1,192	)
	$	3,071		$	2,986

Schedule of changes in the carrying amount of goodwill

The changes in the carrying amount of goodwill during the three months ended March 31, 2017 were as follows (in thousands):

Balances as of December 31, 2016
Goodwill	$	19,156
Accumulated impairment losses		(14,278	)
Goodwill, net	$	4,878
Balances as of March 31, 2017
Goodwill	$	19,156
Accumulated impairment losses		(14,278	)
Goodwill, net	$	4,878

Schedule of intangible assets

The components of the Company’s other intangible assets consist of the following (in thousands):

			March 31, 2017
	Average Amortization
	Period		Gross Carrying		Accumulated			Intangible
	(in years)		Amount		Amortization			Assets, net
Intangibles with definite lives
Acquired FDA non-gel product approval		11	$	1,713	$	(1,701	)	$	12
Customer relationships		9.5		4,940		(855	)		4,085
Trade names - finite life		12		800		(72	)		728
Regulatory approvals		1.17		670		(239	)		431
Non-compete agreement		2.0		80		(27	)		53
Total definite-lived intangible assets			$	8,203	$	(2,894	)	$	5,309
Intangibles with indefinite lives
Trade names - indefinite life	—			450		—			450
Total indefinite-lived intangible assets			$	450	$	—		$	450

			December 31, 2016
	Average Amortization
	Period		Gross Carrying		Accumulated			Intangible
	(in years)		Amount		Amortization			Assets, net
Intangibles with definite lives
Acquired FDA non-gel product approval		11	$	1,713	$	(1,696	)	$	17
Customer relationships		9.5		4,940		(602	)		4,338
Trade names - finite life		12		800		(56	)		744
Regulatory approvals		1.17		670		(96	)		574
Non-compete agreement		2.0		80		(17	)		63
Total definite-lived intangible assets			$	8,203	$	(2,467	)	$	5,736
Intangibles with indefinite lives
Trade names - indefinite life	—			450		—			450
Total indefinite-lived intangible assets			$	450	$	—		$	450

Schedule of estimated amortization expense

The following table summarizes the estimated amortization expense relating to the Company's intangible assets as of March 31, 2017 (in thousands):

	Amortization
Period	Expense
Remainder of 2017	$	1,281
2018		1,090
2019		794
2020		582
2021		435
	$	4,182

Schedule of accrued and other current liabilities

Accrued and other current liabilities consist of the following (in thousands):

	March 31,		December 31,
	2017		2016
Accrued clinical trial and research and development expenses	$	159	$	119
Audit, consulting and legal fees		2,073		803
Payroll and related expenses		2,390		2,592
Accrued commission		2,049		1,222
Warrant liability		178		99
Other		1,513		1,672
	$	8,362	$	6,507